Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.92
NVGN's Cash to Debt is ranked higher than
67% of the 1159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.17 vs. NVGN: 0.92 )
NVGN' s 10-Year Cash to Debt Range
Min: 0.92   Max: No Debt
Current: 0.92

Equity to Asset 0.32
NVGN's Equity to Asset is ranked higher than
51% of the 1084 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. NVGN: 0.32 )
NVGN' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.86
Current: 0.32

0.32
0.86
F-Score: 2
Z-Score: -38.13
M-Score: -7.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -7650.57
NVGN's Operating margin (%) is ranked lower than
57% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. NVGN: -7650.57 )
NVGN' s 10-Year Operating margin (%) Range
Min: -7650.57   Max: -31.89
Current: -7650.57

-7650.57
-31.89
Net-margin (%) -8583.91
NVGN's Net-margin (%) is ranked lower than
57% of the 1110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVGN: -8583.91 )
NVGN' s 10-Year Net-margin (%) Range
Min: -8583.91   Max: 90.46
Current: -8583.91

-8583.91
90.46
ROE (%) -216.46
NVGN's ROE (%) is ranked lower than
57% of the 1139 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.62 vs. NVGN: -216.46 )
NVGN' s 10-Year ROE (%) Range
Min: -269.02   Max: 33.98
Current: -216.46

-269.02
33.98
ROA (%) -116.38
NVGN's ROA (%) is ranked lower than
58% of the 1170 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.52 vs. NVGN: -116.38 )
NVGN' s 10-Year ROA (%) Range
Min: -143.49   Max: 12.06
Current: -116.38

-143.49
12.06
ROC (Joel Greenblatt) (%) -12250.31
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 1165 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.08 vs. NVGN: -12250.31 )
NVGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -9309.09   Max: -69.26
Current: -12250.31

-9309.09
-69.26
Revenue Growth (3Y)(%) -100.00
NVGN's Revenue Growth (3Y)(%) is ranked lower than
55% of the 940 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. NVGN: -100.00 )
NVGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 2
Current: -100

-100
2
EBITDA Growth (3Y)(%) -28.60
NVGN's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 851 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. NVGN: -28.60 )
NVGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.3   Max: 31.5
Current: -28.6

-65.3
31.5
EPS Growth (3Y)(%) -14.50
NVGN's EPS Growth (3Y)(%) is ranked higher than
62% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. NVGN: -14.50 )
NVGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.5   Max: 24.1
Current: -14.5

-62.5
24.1
» NVGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NVGN Guru Trades in

NVGN Guru Trades in

Q2 2013

NVGN Guru Trades in Q2 2013

Jim Simons 15,240 sh (-66.09%)
» More
Q3 2013

NVGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 27.40
NVGN's P/B is ranked lower than
61% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.24 vs. NVGN: 27.40 )
NVGN' s 10-Year P/B Range
Min: 0.95   Max: 13.11
Current: 27.4

0.95
13.11
EV-to-EBIT -8.50
NVGN's EV-to-EBIT is ranked higher than
59% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.13 vs. NVGN: -8.50 )
NVGN' s 10-Year EV-to-EBIT Range
Min: -44   Max: 0.2
Current: -8.5

-44
0.2
Current Ratio 0.81
NVGN's Current Ratio is ranked lower than
54% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. NVGN: 0.81 )
NVGN' s 10-Year Current Ratio Range
Min: 0.81   Max: 9.78
Current: 0.81

0.81
9.78
Quick Ratio 0.81
NVGN's Quick Ratio is ranked higher than
52% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVGN: 0.81 )
NVGN' s 10-Year Quick Ratio Range
Min: 0.81   Max: 8.68
Current: 0.81

0.81
8.68
Days Sales Outstanding 289.48
NVGN's Days Sales Outstanding is ranked higher than
56% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.94 vs. NVGN: 289.48 )
NVGN' s 10-Year Days Sales Outstanding Range
Min: 1.51   Max: 404.33
Current: 289.48

1.51
404.33

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.00
NVGN's Price/Tangible Book is ranked lower than
53% of the 1281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NVGN: 14.00 )
NVGN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 19.5
Current: 14

1.5
19.5
Earnings Yield (Greenblatt) -12.00
NVGN's Earnings Yield (Greenblatt) is ranked lower than
57% of the 1155 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. NVGN: -12.00 )
NVGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 652.6   Max: 4548.1
Current: -12

652.6
4548.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NRT.Australia, NV9.Germany, NV9B.Germany,
Novogen Ltd. was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company's competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.
» More Articles for NVGN

Headlines

Articles On GuruFocus.com
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 
comment on NVGN Mar 06 2013 

More From Other Websites
Novogen Completes the Private Placement of Equity Apr 29 2015
Novogen Regains Full Compliance with NASDAQ Listing Rule Apr 27 2015
Novogen Posts Details on Rights Issue Offering for Shareholders Apr 26 2015
Cantrixil Receives Orphan Drug Designation from FDA Apr 21 2015
Novogen (NVGN) Stock Falls Today on Private Placement Apr 21 2015
Novogen taps investors for $30.5m Apr 21 2015
Novogen Conducts Private Placement and Announces Rights Offering to Shareholders Apr 20 2015
Novogen poised for capital raising Apr 20 2015
Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer Apr 20 2015
Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration Apr 17 2015
Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer Apr 16 2015
Novagen (NVGN) Stock Spiked Today on Melanoma Treatment Study Results Apr 09 2015
Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma Apr 08 2015
Novogen Engages Leading US Investor Relations Firm Apr 01 2015
Novogen shares surge on drug data Mar 30 2015
Yale University and Novogen Release Data on Cantrixil Mode of Action Mar 29 2015
Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study Mar 18 2015
Sky News, Helen Dalley interviews Dr Graham Kelly Mar 09 2015
Cantrixil Data to be Presented at Two Major Conferences Mar 06 2015
Novogen Makes Big Step In Fighting Brain Cancer Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK